Pulmonary hypertension nursing: reference guide for students

Pulmonary hypertension (PH) is sustained elevation of blood pressure within the pulmonary arterial circulation, defined hemodynamically as a mean pulmonary artery pressure (mPAP) of 20 mmHg or greater at rest on right heart catheterization. It is not a single disease — it is a hemodynamic state arising from five distinct pathophysiologic groups, each with different causes, treatment targets, and nursing priorities. Approximately 1% of the global population is affected, with pulmonary arterial hypertension (Group 1, PAH) representing the highest-acuity subgroup. PH carries substantial morbidity: uncorrected, sustained elevation in pulmonary vascular resistance overloads the right ventricle, leading to right ventricular failure and cor pulmonale. Nurses encounter PH patients across medical-surgical, cardiac, and critical care units. This reference covers WHO classification, pathophysiology, diagnosis, PAH-specific pharmacotherapy, nursing priorities, and RV failure recognition — the core content tested on NCLEX and encountered at the bedside. Note that this article covers adult PH and WHO classification; for the neonatal-specific syndrome (persistent pulmonary hypertension of the newborn), see PPHN nursing.

WHO classification of pulmonary hypertension

The World Health Organization classifies PH into five groups based on underlying mechanism and cause. This classification drives treatment decisions — therapies that work in Group 1 PAH are contraindicated or ineffective in Groups 2 and 3.

Clinical implication: PAH-specific vasodilator therapy (prostacyclins, endothelin receptor antagonists, PDE-5 inhibitors) is indicated for Group 1 only. Using these agents in Group 2 PH can worsen outcomes by vasodilating the pulmonary circulation without correcting the elevated left-sided filling pressures, risking acute pulmonary edema.

Pathophysiology

The vascular injury cascade in Group 1 PAH

In pulmonary arterial hypertension, three overlapping processes converge to narrow and stiffen the small pulmonary arteries:

1. Vasoconstriction: Imbalance between vasoconstrictors (endothelin-1, thromboxane A2) and vasodilators (prostacyclin, nitric oxide) causes excessive smooth muscle contraction in pulmonary arteriole walls. This is the earliest and most reversible component — the target of pharmacotherapy.

2. Vascular remodeling: Sustained vasoconstriction triggers pathologic structural changes: smooth muscle cell hypertrophy and proliferation, intimal fibrosis, endothelial dysfunction, and plexiform lesion formation (abnormal endothelial proliferation that partially obliterates vessel lumens). Remodeling increases pulmonary vascular resistance (PVR) irreversibly over time.

3. In situ thrombosis: Endothelial injury and local procoagulant states promote thrombosis within small pulmonary arteries, further reducing the functional vascular bed.

Right ventricular pressure overload

As PVR rises, the right ventricle (RV) must generate higher systolic pressures to maintain forward flow through the lungs. The RV is a thin-walled, low-pressure chamber not designed for sustained pressure work. Its response to chronic pressure overload follows a predictable progression:

• Compensated stage: RV hypertrophy develops (wall thickens to maintain contractility against higher afterload). Cardiac output is preserved at rest.
• Decompensated stage: As PVR continues rising, RV dilation occurs. The enlarged RV shifts the interventricular septum leftward (septal bowing), impairing LV filling. Tricuspid regurgitation develops from annular dilation. Cardiac output drops.
• RV failure and cor pulmonale: End-stage RV failure produces systemic venous congestion (elevated JVP, peripheral edema, hepatomegaly, ascites) and low cardiac output (fatigue, dyspnea, syncope). This is cor pulmonale — right-sided heart failure caused by pulmonary disease.

Hypoxic pulmonary vasoconstriction (Group 3)

In lung disease and hypoxia states, alveolar oxygen tension drops below approximately 60 mmHg. Pulmonary arterioles respond by constricting to redirect blood away from poorly ventilated alveoli toward better-ventilated ones — a ventilation-perfusion matching reflex. Chronic, generalized alveolar hypoxia (as in COPD or advanced interstitial lung disease) produces sustained global vasoconstriction, which over years leads to vascular remodeling similar in appearance to Group 1, though the underlying trigger differs.

Diagnosis

Right heart catheterization — the gold standard

The definitive diagnosis of PH requires right heart catheterization (RHC). Echocardiography can screen for elevated RV pressures and guide clinical suspicion, but RHC provides the hemodynamic measurements that define PH type, severity, and treatment eligibility.

Key hemodynamic parameters measured during RHC:

• mPAP ≥20 mmHg — diagnostic threshold for PH (updated from the historical ≥25 mmHg by the 2022 ESC/ERS guidelines)
• Pulmonary vascular resistance (PVR) ≥2 Wood units — required to define pre-capillary PH (Groups 1, 3, 4, 5)
• Pulmonary artery wedge pressure (PAWP) ≤15 mmHg — distinguishes pre-capillary from post-capillary (Group 2) PH; if PAWP >15 mmHg, left heart disease is the primary driver
• Vasoreactivity testing: During RHC, short-acting vasodilators (inhaled nitric oxide, IV epoprostenol, IV adenosine) are administered. A positive response (mPAP fall ≥10 mmHg to ≤40 mmHg with stable or improved cardiac output) identifies the small subset of IPAH patients (~10%) who may respond to high-dose calcium channel blockers.

Echocardiography (screening and monitoring)

Transthoracic echo is the initial non-invasive screening tool. Findings in PH include:

• Elevated estimated right ventricular systolic pressure (RVSP) via tricuspid regurgitation jet velocity (TR Vmax)
• RV enlargement and hypertrophy
• Flattened or paradoxically moving interventricular septum (D-shaped LV)
• Tricuspid regurgitation
• Dilated right atrium and inferior vena cava

Echo cannot diagnose PH with the precision needed for treatment decisions — it is a screening test that triggers RHC referral when PH is suspected.

Six-minute walk test (6MWT)

The 6-minute walk test measures functional exercise capacity and serves as a surrogate for disease severity and treatment response. The patient walks as far as possible on a flat course in 6 minutes; distance correlates with hemodynamic severity and predicts prognosis. The 6MWT is used at baseline and at follow-up intervals to assess response to PAH-specific therapy. A 6MWT distance below 300–380 meters generally indicates WHO functional class III–IV and more advanced disease.

Clinical note: The 6MWT is not diagnostic but is a key functional assessment that nurses administer and interpret. Document SpO2 throughout — desaturation during the 6MWT has prognostic significance.

PAH-specific pharmacotherapy

PAH-specific therapies target the three main pathways of pulmonary vascular dysregulation: the prostacyclin pathway, the endothelin pathway, and the nitric oxide/cGMP pathway. These drugs are indicated for Group 1 PAH only. They require specialized monitoring and have critical nursing safety considerations.

Combination therapy is now standard in newly diagnosed Group 1 PAH — guidelines support initiating two PAH-specific agents simultaneously (typically an ERA + PDE-5 inhibitor) rather than sequential add-on therapy. Prostacyclins are added in patients with high-risk features or inadequate response. For a broader pharmacology overview, see drug classifications nursing.

Nursing priorities

Oxygen therapy

Target SpO2 ≥90% continuously. Hypoxia is both a symptom and a driver of disease progression — sustained hypoxia worsens pulmonary vasoconstriction (particularly in Groups 3 and 4), accelerating RV pressure overload. In PAH (Group 1), supplemental oxygen may provide modest symptomatic benefit even when resting SpO2 is maintained, particularly during exertion. Titrate oxygen to the individual patient’s target, document resting and exertional saturations, and ensure patients have adequate home oxygen prescriptions if indicated.

Fluid balance

Fluid management in PH requires a careful equilibrium:

• Avoid volume overload: The RV in PH operates on a steep Starling curve — excessive preload causes RV dilation, septal shift, and reduced LV filling. Even modest fluid excess can precipitate acute RV failure in advanced disease. Monitor daily weights, limit IV fluids to replacement of documented losses in stable patients, and report weight gain >2 lbs over 24 hours or 5 lbs over one week.
• Avoid dehydration: Inadequate preload drops RV output and reduces cardiac output. Many PH patients are relatively preload-dependent. Vomiting, diarrhea, excessive diuresis, or reduced oral intake can trigger hemodynamic deterioration. Report signs of volume depletion (orthostasis, rising creatinine, increasing fatigue).
• Diuretic therapy: Most patients with RV failure require loop diuretics (furosemide, torsemide) to manage systemic venous congestion. Monitor electrolytes (potassium, magnesium), renal function (BMP), and daily urine output. Diuresis that is too aggressive worsens RV function.

Activity management

PH patients require individualized activity prescription — neither forced bed rest nor unrestricted activity. Key principles:

• Mild-to-moderate supervised aerobic exercise (e.g., supervised cardiac rehabilitation) improves functional capacity and quality of life in stable Group 1 PAH and is now recommended in guidelines.
• Avoid strenuous isometric exercise (heavy lifting, Valsalva maneuvers) — these sharply increase PVR and can precipitate syncope or acute RV failure.
• Avoid high altitudes (≥5,000 feet) without supplemental oxygen — altitude-induced hypoxia worsens pulmonary vasoconstriction.
• Activity should be self-paced; patients should stop at the onset of presyncope, syncope, or severe dyspnea.

IV prostacyclin line care

Continuous IV epoprostenol and IV/SubQ treprostinil lines require specialized management:

• Never interrupt the infusion. Abrupt discontinuation of IV epoprostenol can cause fatal rebound vasoconstriction within minutes. If a pump alarm sounds or the line becomes disconnected, treat as an emergency — reconnect or restart immediately, call the PAH specialist on call, and monitor the patient for hemodynamic deterioration.
• Use dedicated central lines or PICC lines for IV prostacyclin — never piggyback other medications through the same lumen.
• Cassette/syringe changes must occur on schedule — epoprostenol is prepared in a cassette that must be changed every 24–48 hours depending on formulation and institutional protocol.
• Strict aseptic technique during all line care — sepsis in a patient on IV prostacyclin is a high-risk situation requiring urgent intervention.

Fall prevention and syncope

Syncope is a hallmark symptom of advanced PH and reflects inadequate cardiac output during exertion or vasodilation. It carries significant fall risk and is a red-flag hemodynamic sign. Nursing actions:

• Instruct patients to call for assistance before getting up from bed or chair.
• Apply all standard fall prevention precautions — bed in lowest position, call light within reach, non-slip footwear.
• Report any new syncope or presyncope immediately — it may indicate disease progression, a vasodilatory drug adverse effect, or arrhythmia.
• PAH vasodilators (all classes) produce systemic hypotension as an adverse effect; monitor standing BP particularly during dose titration.

Anticoagulation monitoring

Anticoagulation with warfarin was historically recommended in idiopathic PAH based on the rationale that in situ thrombosis contributes to vascular occlusion. Current evidence is mixed and practice varies by institution and PAH subtype. When anticoagulation is prescribed:

• Monitor INR per institutional protocol (target typically INR 1.5–2.5 in PAH — lower than typical AF targets due to the risk of pulmonary hemorrhage).
• PH patients with Group 4 CTEPH should receive therapeutic anticoagulation long-term to prevent recurrent PE; see pulmonary embolism nursing for anticoagulation monitoring principles.

RV failure recognition

Right ventricular failure in PH can develop insidiously or present as acute decompensation. Early recognition is critical — RV failure is the primary cause of death in PAH. Nurses must distinguish RV failure signs from left-sided heart failure.

High-yield NCLEX tips

NCLEX tip 1: Right heart catheterization is the gold standard The diagnosis of pulmonary hypertension requires right heart catheterization (RHC). Echocardiography can raise suspicion and is used for screening, but it cannot provide the definitive hemodynamic measurements (mPAP, PVR, PAWP) required for diagnosis and classification. When an NCLEX question asks how PH is definitively diagnosed, the answer is right heart catheterization — not echocardiography.

NCLEX tip 2: WHO Group 1 PAH drugs are not for Group 2 PAH-specific vasodilators (prostacyclins, ERAs, PDE-5 inhibitors) are indicated for Group 1 only. Administering these drugs to a patient with Group 2 PH (from left heart disease) can cause acute pulmonary edema by vasodilating the pulmonary circulation on top of already-elevated left-sided filling pressures. Knowing the WHO group is essential before initiating or recognizing appropriate treatment.

NCLEX tip 3: Never interrupt IV prostacyclin Abrupt discontinuation of continuous IV epoprostenol causes rebound pulmonary vasoconstriction that can be fatal within minutes. This is the most safety-critical nursing priority in PAH management. If a question presents a nursing action involving IV prostacyclin, any answer that involves stopping or interrupting the infusion (without immediate reconnection) is incorrect and dangerous. Treat a line disconnection as an emergency.

NCLEX tip 4: Sildenafil and nitrates are absolutely contraindicated together PDE-5 inhibitors (sildenafil, tadalafil) are absolutely contraindicated with organic nitrates and nitric oxide donors. Both drug classes dilate blood vessels — concurrent use produces severe, potentially fatal hypotension. On NCLEX, if a patient is on sildenafil for PAH (or for erectile dysfunction) and is prescribed nitroglycerin for chest pain, the nurse must hold the nitroglycerin and contact the prescriber. This is a hard stop, not a precaution.

NCLEX tip 5: Monitor for syncope — it is a red flag Syncope in PH is not a benign vasovagal event — it reflects an inability to increase cardiac output to meet demand, indicating severely limited cardiac reserve. New exertional syncope in a PH patient warrants immediate reporting, is classified as WHO functional class IV, and may indicate need for urgent escalation of therapy or transplant evaluation. Fall prevention and activity guidance must account for syncope risk in all PH patients.

NCLEX tip 6: Oxygen target is SpO2 ≥90% Maintain continuous SpO2 ≥90% in PH patients. Sustained hypoxia worsens pulmonary vasoconstriction across all PH groups, accelerating RV pressure overload. Supplemental oxygen is both a symptomatic and disease-modifying intervention. In Group 3 PH (from lung disease/hypoxia), correcting the hypoxia is foundational to management — not optional.

NCLEX tip 7: The 6MWT is a functional assessment — not a diagnostic test The six-minute walk test measures functional exercise capacity and is used to assess disease severity and monitor treatment response over time. It is administered by nurses and produces both a walk distance and serial SpO2 readings. A 6MWT distance below 300–380 meters generally indicates WHO functional class III–IV. On NCLEX, the 6MWT appears in questions about monitoring and functional assessment, not diagnosis.

NCLEX tip 8: Pregnancy is contraindicated in severe PAH Pregnancy carries a maternal mortality risk of 30–56% in women with severe PAH — among the highest of any cardiovascular condition in pregnancy. The hemodynamic demands of pregnancy (increased cardiac output, decreased SVR, volume shifts at delivery) are poorly tolerated by the pressure-overloaded, fixed-output RV. Women with PAH should be counseled on contraception before initiating ERA therapy (which is teratogenic) and should receive clear information that pregnancy carries an extreme mortality risk. Endothelin receptor antagonists require mandatory contraception and monthly pregnancy testing via REMS programs.

Related articles

For comprehensive coverage of the conditions that cause or interact with pulmonary hypertension:

• Heart failure nursing — left heart disease is the most common cause of PH worldwide (Group 2); left-sided failure mechanics, diuretic management, and RV–LV interaction
• ARDS nursing — acute hypoxic respiratory failure, hypoxic pulmonary vasoconstriction, and mechanical ventilation considerations
• Pulmonary embolism nursing — acute PE and the risk of CTEPH (Group 4); anticoagulation management
• DVT nursing — deep vein thrombosis as the precursor to PE and CTEPH
• Cystic fibrosis nursing — CF as a Group 3 cause of PH; chronic lung disease and hypoxic vasoconstriction
• PPHN nursing — persistent pulmonary hypertension of the newborn; a neonatal-specific syndrome distinct from adult PH classification
• Drug classifications nursing — PAH pharmacotherapy in the context of broader cardiovascular drug classification

Clinical content reviewed against: 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension; ACC/AHA 2018 Guidelines for Management of Adults with Congenital Heart Disease (PH sections); NIH/NCBI pulmonary hypertension pathophysiology literature; FDA prescribing information for epoprostenol, sildenafil, bosentan, ambrisentan, macitentan, riociguat, treprostinil, and iloprost; Pulmonary Hypertension Association clinical resources. All drug information reflects current US prescribing information.